Alan Zhou
Alan Zhou's practice is focused in the areas of mergers & acquisitions, private equity/venture capital, regulatory compliance, and general corporate. Mr. Zhou has a particularly strong background in pharmaceutical and healthcare industrial sectors. Mr. Zhou has represented many multinational corporations, reputable Chinese state owned and private corporations, and private equity/venture capital funds. He has routinely represented such multinational corporations as Sanofi, Schlumberger, Siemens, Boehringer Ingelheim, Novartis, Aon, Bureau Veritas, Catalent, Terumo, Tosoh, Barclays, Societe Generale Bank, Samsung and SK Telecom. Mr. Zhou has not only worked for reputable Chinese private companies such as Focus Media, VIPShop, Acorn International, Hisoar Pharmaceutical, Tianyuan Biopharm, and GeneScience Pharma, he has also advised PRC state owned companies such as Shanghai Dasheng, Shanghai Industrial and Shanghai Airport Authority. ��In the area of PE/VC, Mr. Zhou has acted for CBRE Investors, Colony Capital, Navis Capital, Lightspeed Ventures, Qiming Ventures, DT Capital, NEA, New Alliance Capital, Warden International, WINS and other international and local PE/VC funds. · Global Law Office
About
Alan Zhou's practice focuses on mergers & acquisitions, private equity/venture capital, regulatory compliance and general corporate matters, with a particular emphasis on the pharmaceutical, healthcare and life sciences sectors. He has represented multinational corporations, PRC state-owned and private companies and numerous PE/VC funds, and was seconded as General Counsel for Boehringer Ingelheim's China operations for more than nine years.
Practice areas
Office
Expertise
Education
- China Europe International Business School — Executive MBA
- College of Law, Shanghai International Studies University — L.L.B.